Merck (NYSE: MRK) is a top healthcare company with one of the best drugs ever made in its portfolio: Keytruda. During the ...

Merck released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA ...

Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

We recently published a list of Jim Cramer Focused On These 9 Stocks Recently. In this article, we are going to take a look ...

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...

NEW YORK, NY / ACCESS Newswire / March 25, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE:MRK) between February 3, 2022 and ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) and reminds investors of the April 14, ...

Trump hinted that the US will impose a 25%+ tariff on pharmaceuticals after giving US companies time to build more ...

CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Merck's expected revenue of $11 billion from sales of Gardasil by 2030. Defendants' ...

Defendants’ statements included, among other things, confidence in Merck’s purported ability to utilize successful consumer activation and education efforts on the benefits of Gardasil in ...